Login| Sign Up| Help| Contact|

Patent Searching and Data

Document Type and Number:
Japanese Patent JPH01104007
Kind Code:
PURPOSE: To obtain a medicine preparation containing an active substance in a stable form, capable of quickly and completely releasing the active substance at a therapeutic site, comprising a micelle prepared by dispersing a monovalent anion-containing cationic surfactant and an antiviral substance for inhibiting a reverse transcriptase into a solvent. CONSTITUTION: This medicine preparation comprises a micelle or a vesicle which is obtained by dispersing 1.0-5.0wt.%, based on the whole medicine preparation, of a monovalent anion-containing cationic surfactant (e.g. 2,5,6-substituted N1 -alkylpyrimidinium compound) and 0.1-1.5wt.% of an antiviral medicine active substance (e.g. azidothymidine or 2',3'-dideoxycytidine) for inhibiting a viral reverse transcriptase into 93.5-98.9wt.% of a solvent having pH 7.0-8.0 and has 1.0×10<-7> to 1.5×10<-4> mol/L critical micelle formation concentration and 500-1,000Å hydrodynamic radius of the micelle or vesicle.

Application Number:
Publication Date:
April 21, 1989
Filing Date:
August 06, 1987
Export Citation:
Click for automatic bibliography generation   Help
International Classes:
A61K9/10; A61K9/107; A61K9/127; A61K31/375; A61K31/395; A61K31/41; A61K31/415; A61K31/4184; A61K31/425; A61K31/426; A61K31/428; A61K31/44; A61K31/4418; A61K31/4425; A61K31/46; A61K31/47; A61K31/49; A61K31/496; A61K31/505; A61K31/52; A61K31/522; A61K31/53; A61K31/65; A61K31/66; A61K33/24; A61K33/28; A61K33/30; A61K31/70; A61K33/42; A61K45/08; A61K47/00; A61K47/18; A61K47/22; A61P17/00; A61P17/16; A61P31/04; A61P31/12; A61P35/00; A61P43/00; C07C67/00; C07C213/00; C07C217/08; C07D209/00; C07D213/00; C07D213/20; C07D213/30; C07D213/63; C07D213/65; C07D213/68; C07D213/69; C07D213/73; C07D213/79; C07D213/80; C07D213/81; C07D213/82; C07D215/10; C07D215/18; C07D231/00; C07D231/12; C07D231/18; C07D231/20; C07D231/28; C07D233/00; C07D233/54; C07D233/58; C07D235/00; C07D235/06; C07D239/00; C07D239/26; C07D239/30; C07D239/36; C07D239/46; C07D239/47; C07D239/54; C07D239/553; C07D241/00; C07D241/12; C07D241/18; C07D241/24; C07D249/08; C07D251/18; C07D251/70; C07D277/00; C07D277/22; C07D277/62; C07D307/62; C07D471/04; C07D473/00; C07D473/04; C07D473/06; C07D473/16; C07D473/18; C07D473/28; C07D473/30; C07D473/32; C07D473/34; C07D473/38; C07D473/40; C07D487/04; C07D521/00; C09K23/18; C09K23/32; C12N9/99; G01N33/52; G01N33/532; G01N33/543; G01N33/544; G01N33/58; (IPC1-7): A61K9/10; A61K31/375; A61K31/395; A61K31/41; A61K31/46; A61K31/53; A61K31/65; A61K31/66; A61K31/70; A61K31/71; A61K33/28; B01F17/32; C07; C07C93/04; C07D213/20; C07D213/68; C07D213/79; C07D215/10; C07D231/12; C07D231/18; C07D233/58; C07D235/06; C07D239/26; C07D239/36; C07D239/47; C07D239/54; C07D239/55
Attorney, Agent or Firm:
Shintaro Nogawa